# LUOSICNS (osimertinib): what clinicians are saying

> 39 statements from 12 sources (1 video, 10 posts, 1 paper), 12 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
- NCT ID: NCT03769103
- Registry: https://clinicaltrials.gov/study/NCT03769103
- Sponsor: British Columbia Cancer Agency
- Phase: Phase 2
- Status: Unknown
- Drugs tested: osimertinib
- Indication: treatment-naïve EGFR-mutated NSCLC with brain metastases
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: 774781f4a4077c9fac3d70643c79194b8f3ff3d7353439c25672c12417de8f24

## Counts

- Commentary sources screened: 21
- Sources cited by verified statements: 12
- Verified statements: 39
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 12
- Findings: 5
- Named people in screened sources (unnamed speakers and accounts not counted): 13
- Speakers cited: 13
- Cited speakers with a verified identity: 10
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 6
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 6
- By role and specialty (the abstract's specialty counts):
  - 4 physician, Medical oncology
  - 2 physician, Radiation oncology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

One speaker reads LUOSICNS within STARLET as supporting osimertinib first with close MRI surveillance, citing SRS use at progression, but does not extend that reassurance to symptomatic disease or greater intracranial burden. A medical oncologist would selectively consider upfront SRS plus osimertinib because of the survival signal, while another stresses that the difference was not statistically significant. Long-term neurocognitive protection remains unresolved.

## Question clinicians left open

In treatment-naïve EGFR-mutated NSCLC with brain metastases, what do clinicians say remains unresolved when choosing upfront SRS plus osimertinib versus osimertinib with MRI surveillance and SRS at progression, including symptomatic or high-burden disease and prevention of long-term neurocognitive impairment?

From finding F1 (13 statements from 5 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. SRS timing: how speakers choose upfront use or deferral with close MRI follow-up
  - 13 statements from 5 speakers in 7 sources, 1 of them a podcast or video.
  - 5 of the 5 named speakers in this finding take a side on this question.
  - 2 of the report's 6 cited clinicians.
- F2. OS medians: where speakers split on how to interpret them
  - 7 statements from 4 speakers in 4 sources.
  - 4 of the 4 named speakers in this finding take a side on this question: 2 on one side, 2 on the other.
  - 2 of the report's 6 cited clinicians.
- F3. Added SRS: what speakers say
  - 7 statements from 4 speakers in 5 sources, 1 of them a podcast or video.
  - 1 of the report's 6 cited clinicians.
- F4. Upfront SRS: a clinician favors systemic therapy first but discusses high-risk cases
  - 5 statements from 1 speaker in 2 sources.
  - The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “discuss high-risk cases”.
  - 1 of the report's 6 cited clinicians.
- F5. STARLET: most speakers question precision, but one sees it changing practice
  - 11 statements from 5 speakers in 6 sources, 1 of them a podcast or video.
  - 4 of the 5 named speakers in this finding hold this view; 1 of them holds its caveat, “one sees it changing practice”.
  - 2 of the report's 6 cited clinicians.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 13 | 10 | 7 | 5 | 4 |
| F2 | 7 | 7 | 4 | 4 | 4 |
| F3 | 7 | 5 | 5 | 4 | 5 |
| F4 | 5 | 3 | 2 | 1 | 4 |
| F5 | 11 | 9 | 6 | 5 | 5 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 10 | 1 | 1 | 0 | 1 | 14 | 1 | 5 posts and articles, 1 podcast or video, 1 publication |
| F2 | 4 | 1 | 0 | 0 | 2 | 7 | 0 | 3 posts and articles, 1 publication |
| F3 | 4 | 1 | 0 | 0 | 2 | 7 | 0 | 3 posts and articles, 1 podcast or video, 1 publication |
| F4 | 3 | 0 | 0 | 1 | 1 | 5 | 1 | 1 post or article, 1 publication |
| F5 | 4 | 3 | 1 | 0 | 3 | 11 | 1 | 4 posts and articles, 1 podcast or video, 1 publication |

### Trial dimensions

- Primary endpoint: Intracranial progression free survival: F1 (2 shared claims), F3 (1 shared claims), F5 (3 shared claims)
- Secondary endpoints: F1 (4 shared claims), F2 (6 shared claims), F3 (4 shared claims), F5 (1 shared claims)
- Population and setting: F1 (6 shared claims), F3 (2 shared claims), F4 (2 shared claims), F5 (1 shared claims)
- The comparison: F1 (7 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (2 shared claims), F5 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F3 (5 shared claims), F4 (1 shared claims), F5 (2 shared claims)
- Design and conduct: F1 (1 shared claims), F3 (1 shared claims), F5 (7 shared claims)

## Abbreviations

- CNS: central nervous system
- EGFR: epidermal growth factor receptor
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- MRI: magnetic resonance imaging
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer
- OS: overall survival

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 5 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 39 | Paid |
| Who said each statement: the cited speakers | 13 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 6 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 10 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 10 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 6 of the 13 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

10 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Intracranial progression free survival | discussed | 6 | 5 |
| Secondary endpoints | discussed | 12 | 5 |
| Population and setting | discussed | 9 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 11 | 7 |
| Safety and tolerability | discussed | 7 | 6 |
| Design and conduct | discussed | 7 | 4 |
| MRI surveillance and salvage-SRS timing | discussed | 4 | 3 |
| CNS-risk stratification and patterns of failure | discussed | 3 | 1 |
| Evidence expansion and feasibility of further trials | discussed | 4 | 2 |
| Guideline alignment and interpretation of the prior evidence gap | discussed | 3 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 7 statements · 18%** | | | |
| YouTube | 7 | 1 | 1 |
| **Posts · 28 statements · 72%** | | | |
| X threads | 13 | 7 | 14 |
| LinkedIn posts | 15 | 3 | 3 |
| Bluesky threads | 0 | 0 | 3 |
| **Primary sources · 4 statements · 10%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 4 | 1 | not screened |

- Screened window: 2023-06-01 to 2026-11-01
- Cited window: 2023-06-01 to 2026-11-01
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: Open Label, Multicenter, Phase II Study of Patients With Treatment Naïve Metastatic Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases Randomized to Stereotactic Radiosurgery (SRS) and Osimertinib or Osimertinib Alone
- Registry: NCT03769103 (https://clinicaltrials.gov/study/NCT03769103)
- Study IDs: LUOSICNS
- Sponsor: British Columbia Cancer Agency
- Collaborators: AstraZeneca, Princess Margaret Hospital, Canada, Sunnybrook Health Sciences Centre
- Design: Phase 2 · interventional, randomized, parallel, phase2
- Status: Unknown
- Enrollment: 40 (actual)
- Start: 2019-03-19 (actual)
- Primary completion: 2025-04 (estimated)
- Primary endpoint: Intracranial progression free survival (1 year)
- Intervention: Osimertinib (drug)
- Intervention: Stereotactic radiotherapy (radiation)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 12 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 36 sources about other trials or topics are not included; discussion that refers to the trial only by a name it shares with other things may be missing.
- The sources reviewed for this edition do not represent all HCPs or all public discussion. Discussion without explicit trial names or with different transcription variants may be missing, and some potentially relevant discussions were not examined in full.
- Publication-linked posts, replies, conference reporting and the interview are not interchangeable or necessarily independent assessments. Reposts do not establish endorsement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The pooled publication reports 79 randomized participants, while a speaker says 80 in the interview account of their own study. Neither total should be substituted for the other without explanation.
- The publication abstract reports OS medians without an OS significance test. Statements about OS nonsignificance, power and the reason for uncertainty remain attributed to their speakers.
- The quality-of-life discussion concerns specified patient-reported domains; it does not establish objective neurocognitive equivalence or prevention of late impairment.
- A speaker's risk associations and treatment interpretation come from a separate retrospective study and cannot establish which patients benefit from upfront SRS or WBRT.
- A standalone protocol was not available in the sources reviewed, limiting assessment of protocol details beyond the publication and registry context.
- Earlier comments that outcomes were awaited are dated historical views, not statements that STARLET results remain unavailable.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 39 verified statements · 12 from 6 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (10 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/luosicns-nct03769103
- Agents: POST https://www.erudio.com/api/orders with {"report": "luosicns-nct03769103", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=luosicns-nct03769103

## Cite

Erudio Health. LUOSICNS (NCT03769103): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/luosicns-nct03769103

## Questions

### How much does the LUOSICNS report cost?

One edition costs $750 (Focused · 39 verified statements · 12 from 6 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the LUOSICNS report cover?

39 statements from 12 sources (1 video, 10 posts, 1 paper), 12 of them from 6 confirmed clinicians, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the LUOSICNS report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "luosicns-nct03769103" }) previews it and create_order({ "report": "luosicns-nct03769103", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the LUOSICNS report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/luosicns-nct03769103.json
- Markdown: https://www.erudio.com/reports/luosicns-nct03769103.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/luosicns-nct03769103/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "luosicns-nct03769103"}`
